Deutsch English Français

Contact

EP2432761

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2432761

EP2432761 - TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 08.12.2017 Database last updated on 09.09.2024
Former	Grant of patent is intended Status updated on 24.02.2017
Most recent event Tooltip	08.12.2017	Application deemed to be withdrawn	published on 10.01.2018 [2018/02]
Applicant(s)	For all designated states Ottawa Hospital Research Institute 725 Parkdale Avenue Ottawa, ON K1Y 4E9 / CA
	For all designated states Fate Therapeutics (Canada) Inc. c/o 3535 General Atomics Court Suite 200 San Diego, California 92121 / US
	[N/P]
Former [2012/13]	For all designated states Ottawa Hospital Research Institute 725 Parkdale Avenue Ottawa, ON K1Y 4E9 / CA
	For all designated states Fate Therapeutics (Canada) Inc. C/o 3535 General Atomics Court Suite 200 San Diego, California 92121 / US
Inventor(s)	01 / MEGENEY, Lynn 1609 Alta Vista Drive Ottawa Ontario K1G 0G4 / CA
	02 / EVANS, Carol 61 Clifford Private Ottawa Ontario KlG 4Y2 / CA
	03 / SLASSI, Abdelmalik 4780 Fulwell Road Mississauga Ontario L5M 7J7 / CA
	[N/P]
Former [2012/13]	01 / MEGENEY, Lynn 1609 Alta Vista Drive Ottawa Ontario K1G 0G4 / CA
	02 / EVANS, Carol 61 Clifford Private Ottawa Ontario KlG 4Y2 / CA
	03 / SLASSI, Abdelmalik 4780 Fulwell Road Mississauga Ontario L5M 7J7 / CA
Representative(s)	Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
	[N/P]
Former [2012/13]	Schiweck, Weinzierl & Koch European Patent Attorneys Landsberger Straße 98 80339 München / DE
Application number, filing date	10777262.6	18.05.2010
	WO2010CA00734
Priority number, date	US20090179040P	18.05.2009 Original published format: US 179040 P
	US20090244669P	22.09.2009 Original published format: US 244669 P
	[2012/13]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010132982
	Date:	25.11.2010
	Language:	EN
	[2010/47]
	Type:	A1 Application with search report
	No.:	EP2432761
	Date:	28.03.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 25.11.2010 takes the place of the publication of the European patent application.
	[2012/13]
Search report(s)	International search report - published on:	CA	25.11.2010
	(Supplementary) European search report - dispatched on:	EP	13.11.2012
Classification	IPC:	A61K31/155, A61P21/00	[2012/50]
	CPC:	C07C313/30 (EP,US); A61K31/155 (EP,US); A61P21/00 (EP); C07F9/657154 (EP,US); C07C2601/14 (EP,US); G01N2333/62 (EP,US); (+) G01N2800/10 (EP,US); G01N2800/52 (EP,US) (-)
	Former IPC [2012/13]	C07C279/26, A61K31/155, A61P21/00, C07C313/30, G01N33/74
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/13]
Title	German:	VERFAHREN ZUR BEHANDLUNG VON DURCH INSULINRESISTENZ GEKENNZEICHNETEN MUSKELERKRANKUNGEN	[2012/13]
	English:	TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE	[2012/13]
	French:	TRAITEMENT D'UNE MALADIE MUSCULAIRE CARACTÉRISÉE PAR UNE RÉSISTANCE À L'INSULINE	[2012/13]
Entry into regional phase	12.12.2011	National basic fee paid
	12.12.2011	Search fee paid
	12.12.2011	Designation fee(s) paid
	12.12.2011	Examination fee paid
Examination procedure	12.12.2011	Examination requested [2012/13]
	04.06.2013	Amendment by applicant (claims and/or description)
	28.10.2013	Despatch of a communication from the examining division (Time limit: M02)
	23.12.2013	Reply to a communication from the examining division
	22.01.2014	Despatch of a communication from the examining division (Time limit: M04)
	30.05.2014	Reply to a communication from the examining division
	13.04.2015	Despatch of a communication from the examining division (Time limit: M02)
	22.06.2015	Reply to a communication from the examining division
	19.11.2015	Despatch of a communication from the examining division (Time limit: M02)
	29.01.2016	Reply to a communication from the examining division
	03.03.2017	Communication of intention to grant the patent
	14.07.2017	Application deemed to be withdrawn, date of legal effect [2018/02]
	23.08.2017	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2018/02]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.10.2013
Fees paid	Renewal fee
	25.05.2012	Renewal fee patent year 03
	28.05.2013	Renewal fee patent year 04
	27.05.2014	Renewal fee patent year 05
	27.05.2015	Renewal fee patent year 06
	27.05.2016	Renewal fee patent year 07
	Penalty fee
	Additional fee for renewal fee
	31.05.2017	08 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[E]WO2011121109 (INST NAT SANTE RECH MED [FR], et al) [E] 1-8,12-14 * claims 1-12 *;
		[AP]WO2009112439 (JANSSEN PHARMACEUTICA NV [BE], et al) [AP] 1-14 * table 3 * * claim 16 *;
		[E]WO2010080581 (UNIV NEVADA [US], et al) [E] 1-8 * claim 23 *
		[XI] - KASHIWAGI KEN-ICHIRO ET AL, "Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy", BIOSIS,, (19990401), XP002594594 [X] 1-4,7,8 * the whole document * [I] 5,6,9-11
	International search	[A]WO2007134867 (DSM IP ASSETS BV [NL], et al);
		[X]GB607720 (ARTHUR DONALD AINLEY, et al);
		[X]US3152181 (LOUIS FREEDMAN, et al);
		[X]US3366650 (JACK BERNSTEIN, et al);
		[X]US3147271 (SHAPIRO SEYMOUR L, et al);
		[X]US3531484 (BICKING JOHN B, et al);
		[X]US5434142 (ANTOKU YASUNOBU [JP], et al);
		[XP] - HUTTUNEN, K.M. ET AL., J. MED. CHEM., (20090612), vol. 52, pages 4142 - 4148, XP008152149 DOI: http://dx.doi.org/10.1021/jm900274q
		[X] - HUTTUNEN, K.M. ET AL., "Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatography", J. PHARMA. BIOMED. ANALYSIS, (20090507), vol. 50, pages 469 - 474, XP026321335 DOI: http://dx.doi.org/10.1016/j.jpba.2009.04.033
		[X] - HUTTUNEN, K.M. ET AL., SYNTHESIS, (2008), pages 3619 - 3624, XP008152150 DOI: http://dx.doi.org/10.1055/s-0028-1083603
		[AP] - ABE, H. ET AL., ENDOCRINE JOURNAL 2009, (20090609), vol. 56, pages 911 - 913, XP008152633 DOI: http://dx.doi.org/10.1507/endocrj.K09E-122
		[A] - KOUKI, T. ET AL., DIABETIC MEDICINE, (2005), vol. 22, pages 346 - 347, XP008152153 DOI: http://dx.doi.org/10.1111/j.1464-5491.2005.01432.x
		[A] - PICCARDO, M.G. ET AL., ENZYME, (1991), vol. 45, pages 14 - 22, XP008154276
		[X] - ANGELINI, C. ET AL., MUSCLE NERVE, (2007), vol. 36, pages 424 - 435, XP008152182 DOI: http://dx.doi.org/10.1002/mus.20812
		[X] - AINLEY, A.D. ET AL., J. CHEM. SOC., (1949), pages 98 - 106, XP008154353 DOI: http://dx.doi.org/10.1039/jr9490000098
		[X] - SRINIVAS, K.S. ET AL., J. INDIAN. INST. SCI., (1953), vol. 35 A, pages 47 - 54, XP008152152
		[X] - RUNTI, C. ET AL., IL FARMACO, (1968), vol. 23, pages 827 - 841
		[X] - COLAUTTI, A. ET AL., IL FARMACO, (1971), vol. 26, pages 850 - 856, XP008152187
		[X] - LIU, Z. ET AL., "The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, inalloxan- and streptozocin-induced diabetic rats", CHEMICO-BIOLOGICAL INTERACTIONS, (2008), vol. 173, pages 68 - 75, XP022612926 DOI: http://dx.doi.org/10.1016/j.cbi.2007.11.012
		[X] - SHAPIRO, S. L. ET AL., J. AM. CHEM. SOC., (1959), vol. 81, pages 4635 - 4639, XP008154896 DOI: http://dx.doi.org/10.1021/ja01526a047
		[X] - DUAN, Z-L. ET AL., "Synthesis and Study of Antidiabetic Properties of the Neodymium Complexe with N- [o-(un) Substituted Benzoyl]-N, N-Dimethylbiguanide", CHINESE J. CHEM., (2007), vol. 25, pages 1919 - 1923, XP008153160 DOI: http://dx.doi.org/10.1002/cjoc.200790353
		[X] - KHAN, M. A. ET AL., J. NERUOL. SCI., (1993), vol. 120, pages 8 - 14, XP024298817 DOI: http://dx.doi.org/10.1016/0022-510X(93)90017-S
	by applicant	WO2011121109
		WO2010080581
		- HUTTUNEN ET AL., J. MED. CHEM., (2009), vol. 52, pages 4142 - 4148
		- HUTTUNEN ET AL., J. PHARMA. BIOMED. ANALYSIS, (2009), vol. 50, pages 469 - 474
		- HUTTUNEN ET AL., SYNTHESIS, (2008), pages 3619 - 3624
		- ABE ET AL., ENDOCRINE JOURNAL, (2009), vol. 56, pages 911 - 913
		- KOUKI ET AL., DIABETIC MEDICINE, (2005), vol. 22, pages 346 - 347
		- ANGELINI ET AL., MUSCLE NERVE, (2007), vol. 26, pages 424 - 435
		- KHAN ET AL., J NEUROL. SCI., (1993), vol. 120, pages 8 - 14
		- HOFFMAN ET AL., N. ENGL. J. MED., (1988), vol. 318, pages 1363 - 1368
		- BONNEMANN, C. G. ET AL., CURR. OPIN. PED., (1996), vol. 8, pages 569 - 582
		- WORTON, R., SCIENCE, (1995), vol. 270, pages 755 - 756
		- FUNAKOSHI, M. ET AL., NEUROMUSCUL. DISORD., (1999), vol. 9, no. 2, pages 108 - 114
		- LIM, L. E.; CAMPBELL, K. P., CURE. OPIN. NEUROL., (1998), vol. 11, no. 5, pages 443 - 452
		- VOIT, T., BRAIN DEV., (1998), vol. 20, no. 2, pages 65 - 74
		- BROWN, R. H., ANNU. REV. MED., (1997), vol. 48, pages 457 - 466
		- FISHER, J.; UPADHYAYA, M., NEUROMUSCUL. DISORD., (1997), vol. 7, no. 1, pages 55 - 62
		- E. L. ELIEL; S. H. WILEN, Stereochemistry of Carbon Compounds, JOHN WILEY & SONS, (1994), pages 1119 - 1190
		- MERRIFELD, AM. CHEM. SOC., (1963), vol. 85, page 2149
		- MERRIFELD, SCIENCE, (1986), vol. 232, page 341
		- BITTNER ET AL., METHODS IN ENZYMOL., (1987), vol. 153, page 516
		- ZAMORE, NATURE STRUC. BIOL., (2001), vol. 8, pages 746 - 750
		- Current Protocols in Protein Science, J. WILEY & SONS
		- SHARP NJ ET AL., GENOMICS, (1992), vol. 13, no. 1, pages 115 - 121
		- WILLMANN R. ET AL., NEUROMUSCULAR DISORDERS, (2009), vol. 19, pages 241 - 249
		- VAINZOF M. ET AL., J MOL NEUROSCI., (2008), vol. 34, no. 3, pages 241 - 8
		- MEGENEY ET AL., GENES DEV., (1996), vol. 10, pages 1173 - 1183
		- ASAKURA ET AL., J: CELL BIOL., (2000), vol. 159, pages 123 - 134
		- ABRAMOVICI, H.; HOGAN, A.B.; OBAGI, C.; TOPHAM, M.K.; GEE, S.H., "Diacylglycerol kinasezeta localization in skeletal muscle is regulated by phosphorylation and interaction with syntrophins", MOL BIOL CELL, (2003), vol. 14, pages 4499 - 4511
		- AGUIRRE, V.; UCHIDA, T.; YENUSH, L.; DAVIS, R.; WHITE, M.F., "The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307", J BIOL CHEM., (2000), vol. 275, pages 9047 - 9054
		- BAILEY CJ; PUAH JA, "Effect of metformin on glucose metabolism in mouse soleus muscle", DIABETE METAB, (1986), vol. 12, pages 212 - 8
		- BARTON, E.R.; MORRIS, L.; MUSARO, A.; ROSENTHAL, N.; SWEENEY, H.L., "Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice", J CELL BIOL., (2002), vol. 157, pages 137 - 148
		- BARTON, E.R., "The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair", APPL PHYSIOL NUTR METAB., (2006), vol. 31, pages 791 - 797
		- BLAAUW, B.; MAMMUCARI, C.; TONIOLO, L.; AGATEA, L.; ABRAHAM, R.; SANDRI, M.; REGGIANI, C.; SCHIAFFINO, S., "Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle", HUM MOL GENET., (2008), vol. 17, pages 3686 - 3696
		- CHAKKALAKAL, J.V.; HARRISON, M.A.; CARBONETTO, S.; CHIN, E.; MICHEL, R.N.; JASMIN, B.J., "Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice", HUM MOL GENET., (2004), vol. 13, pages 379 - 388
		- CHAKKALAKAL, J.V.; THOMPSON, J.; PARKS, R.J.; JASMIN, B.J., "Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies", FASEB J., (2005), vol. 19, pages 880 - 891
		- CHAKKALAKAL, J.V.; MICHEL, S.A.; CHIN, E.R.; MICHEL, R.N.; JASMIN, B.J., "Targeted inhibition of Ca2+ /calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle", HUM MOL GENET., (2006), vol. 15, pages 1423 - 1435
		- CHEN, Y.W.; ZHAO, P.; BORUP, R.; HOFFMAN, E.P., "Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology", J CELL BIOI., (2000), vol. 151, pages 1321 - 1336
		- CHIN, E.R.; OLSON, E.N.; RICHARDSON, J.A.; YANG, Q.; HUMPHRIES, C.; SHELTON, J.M.; WU, H.; ZHU, W.; BASSEL-DUBY, R.; WILLIAMS, R.S, "A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type", GENES DEV., (1998), vol. 12, pages 2499 - 2509
		- CHO DH. ET AL., "Myotonic dystrophy: emerging mechanisms for DM1 and DM2", BIOCHIM BIOPHYS ACTA, (2007), vol. 1772, no. 2, pages 195 - 204
		- CHUNG, J.; NGUYEN, A.K.; HENSTRIDGE, D.C.; HOLMES, A.G.; CHAN, M.H.; MESA, J.L.; LANCASTER, G.I.; SOUTHGATE, R.J.; BRUCE, C.R.; DU, "HSP72 protects against obesity-induced insulin resistance", PROC NATL ACAD SCI U S A., (2008), vol. 105, pages 1739 - 1744
		- COHEN SE; TSENG YH; MICHAEL MD; KAHN CR, "Effects of insulin-sensitising agents in mice with hepatic insulin resistance", DIABETOLOGIA, (2004), vol. 47, pages 407 - 11
		- ERVASTI, J.M.; SONNEMANN, K.J., "Biology of the striated muscle dystrophin-glycoprotein complex", INT REV CYTOL., (2008), vol. 265, pages 191 - 225
		- EVEN, P.C.; DECROUY, A.; CHINET, A., "Defective regulation of energy metabolism in mdxmouse skeletal muscles", BIOCHEM J., (1994), vol. 304, pages 649 - 654
		- FREUND AA. ET AL., ARG. NEURO ARG. NEUROPSIQIATR., (2007), vol. 65, no. 1, pages 73 - 6
		- GREGOREVIC, P.; PLANT, D.R.; LYNCH, G.S., "Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice", MUSCLE NERVE, (2004), vol. 30, pages 295 - 304
		- GUGLIERI M. ET AL., "Limb-Girdle muscular dystrophies", CURR OPIN NEUROL., (2008), vol. 21, no. 5, pages 576 - 84
		- HASEGAWA, M.; CUENDA, A.; SPILLANTINI, M.G.; THOMAS, G.M.; BUEE-SCHERRER, V.; COHEN, P.; GOEDERT, M., "Stress-activated protein kinase-3 interacts with the PDZ domain of alpha 1-syntrophin. A mechanism for specific substrate recognition", J BIOL CHEM., (1999), vol. 274, pages 12626 - 12631
		- HILDER, T.L.; TOU, J.C.; GRINDELAND, R.E.; WADE, C.E.; GRAVES, L.M., "Phosphorylation of insulin receptor substrate-1 serine 307 correlates with JNK activity in atrophic skeletal muscle", FEBS LETT., (2003), vol. 553, pages 63 - 67
		- HIROSUMI, J.; TUNCMAN, G.; CHANG, L.; GORGUN, C.Z.; UYSAL, K.T.; MAEDA, K.; KARIN, M.; HOTAMISILGIL, G.S., "A central role for JNK in obesity and insulin resistance", NATURE, (2002), vol. 420, pages 333 - 336
		- HAN, HYO-KYUNG, AAPS PHARMSCI., (2000), vol. 2, no. 1
		- HUTTUNEN KM. ET AL., J. MED. CHEM., (2009), vol. 52, no. 14, pages 4142 - 8
		- HUTTUNEN KM. ET AL., SYNTHESIS, (2008), vol. 22, pages 3619 - 3624
		- KHAIRALLAH, M.; KHAIRALLAH, R.; YOUNG, M.E.; DYCK, J.R.; PETROF, B.J.; DES ROSIERS, C., "Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy", J MOL CELL CARDIOL., (2007), vol. 43, pages 119 - 129
		- LANGENBACH, K.J.; RANDO, T.A., "Inhibition of dystroglycan binding to laminin disrupts the P13K/AKT pathway and survival signaling in muscle cells", MUSCLE NERVE, (2002), vol. 26, pages 644 - 653
		- LIQUORI CL. ET AL., "Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9", SCIENCE, (20001203), vol. 293, no. 5531, pages 864 - 7
		- LIZCANO, J.M.; ALESSI, D.R., "The insulin signalling pathway", CURR BIOL., (2002), vol. 12, pages R236 - 238
		- LUMENG, C.; PHELPS, S.; CRAWFORD, G.E.; WALDEN, P.D.; BARALD, K.; CHAMBERLAIN, J.S., "Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases", NAT NEUROSCI., (1999), vol. 2, pages 611 - 617
		- NOGRADY, Medicinal Chemistry A Biochemical Approach, OXFORD UNIVERSITY PRESS, (1985), pages 388 - 392
		- MADHAVAN, R.; JARRETT, H.W., "Calmodulin-activated phosphorylation of dystrophin", BIOCHEMISTRY, (1994), vol. 33, pages 5797 - 5804
		- MADHAVAN, R.; JARRETT, H.W., "Phosphorylation of dystrophin and alpha-syntrophin by Ca(2+)-calmodulin dependent protein kinase 11", BIOCHIM BIOPHYS ACTA, (1999), vol. 1434, pages 260 - 274
		- MISRA, P., "AMP activated protein kinase: a next generation target for total metabolic control", EXPERT OPIN THER TARGETS, (2008), vol. 12, pages 91 - 100
		- MOKHTARIAN, A.; DECROUY, A.; CHINET, A.; EVEN, P.C., "Components of energy expenditure in the mdx mouse model of Duchenne muscular dystrophy", PFLUGERS ARCH., (1996), vol. 431, pages 527 - 532
		- MUSARO, A.; MCCULLAGH, K.J.; NAYA, F.J.; OLSON, E.N.; ROSENTHAL, N., "IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1", NATURE, (1999), vol. 400, pages 581 - 585
	- MUSI N; HIRSHMAN MF; NYGREN J; SVANFELDT M; BAVENHOLM P; ROOYACKERS 0; ZHOU G; WILLIAMSON JM; LJUNQVIST 0; EFENDIC S, "Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes", DIABETES, (2002), vol. 51, pages 2074 - 2081
	- MUSI N; GOODYEAR LJ, "Insulin resistance and improvements in signal transduction", ENDOCRINE, (2006), vol. 29, pages 73 - 80
	- NAYA, F.J.; MERCER, B.; SHELTON, J.; RICHARDSON, J.A.; WILLIAMS, R.S.; OLSON, E.N., "Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo", J BIOL CHEM., (2000), vol. 275, pages 4545 - 4548
	- NOGUCHI, S., "The biological function of insulin-like growth factor-I in myogenesis and its therapeutic effect on muscular dystrophy", ACTA MYOL., (2005), vol. 24, pages 115 - 118
	- PETER, A.K.; KO, C.Y.; KIM, M.H; HSU, N.; OUCHI, N.; RHIE, S.; IZUMIYA, Y.; ZENG, L.; WALSH, K.; CROSBIE, R.H., "Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy", HUM MOL GENET., (2009), vol. 18, pages 318 - 327
	- PETROF, B.J.; SHRAGER, J.B.; STEDMAN, H.H.; KELLY, A.M.; SWEENEY, H.L., "Dystrophin protects the sarcolemma from stresses developed during muscle contraction", PROC NATL ACAD SCI USA., (1993), vol. 90, pages 3710 - 3714
	- ST-PIERRE, S.J.G.; KOLODZIEJCZYK, S.M.; KNUDSON, J.C.; CHAKKALLAL, J.; JASMIN, B.; MEGENEY LA., "Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway", FASEB J., (2004), vol. 18, pages 1937 - 1939
	- SANDRI, M.; SANDRI, C.; GILBERT, A.; SKURK, C.; CALABRIA, E.; PICARD, A.; WALSH, K.; SCHIAFFINO, S.; LECKER, S.H.; GOLDBERG, A.L., "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy", CELL., (2004), vol. 117, pages 399 - 412
	- SEMSARIAN, C.; WU, M.J.; JU, Y.K.; MARCINIEC, T.; YEOH, T.; ALLEN, D.G.; HARVEY, RP.; GRAHAM, RM., "Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signaling pathway", NATURE, (1999), vol. 400, pages 576 - 581
	- SEWRY CA., J MUSCLE RES CELL MOTIL., (2008), vol. 29, no. 6-8, pages 231 - 8
	- SCHERTZER, J.D.; LYNCH, G.S., "Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury", GENE THER., (2006), vol. 13, pages 1657 - 1664
	- SCHERTZER, J.D.; RYALL, J.G.; LYNCH, G.S., "Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice", AM J PHYSIOL ENDOCRINOL METAB., (2006), vol. 291, pages E499 - E505
	- STELLA VJ ET AL., DRUGS, (1985), vol. 29, pages 455 - 473
	- STEBBINS ET AL., PNAS, (20081028), vol. 105, no. 43, pages 16809 - 16813
	- STITT, T.N.; DRUJAN, D.; CLARKE, B.A.; PANARO, F.; TIMOFEYVA, Y.; KLINE, W.O.; GONZALEZ, M.; YANCOPOULOS, G.D.; GLASS, D.J., "The IGF-1/P13K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors", MOL CELL, (2004), vol. 14, pages 395 - 403
	- STUPKA, N.; PLANT, D.R.; SCHERTZER, J.D.; EMERSON, T.M.; BASSEL-DUBY, R.; OLSON, E.N.; LYNCH, G.S., "Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice", J PHYSIOL., (2006), vol. 575, pages 645 - 656
	- STUPKA, N.; SCHERTZER, J.D.; BASSEL-DUBY, R.; OLSON, E.N.; LYNCH, G.S., "Stimulation of calcineurin A{apha} activity attenuates muscle pathophysiology in mdx dystrophic mice", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL., (2008), vol. 294, pages R983 - R992
	- SUWA M; EGASHIRA T; NAKANO H; SASAKI H; KUMAGAI S, "Metformin increases the PGC-1 alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo", J APPL PHYSIOL., (2006), vol. 101, pages 1685 - 1692
	- TAWIL R., "Facioscapulohumeral muscular dystrophy", NEUROTHERAPEUTICS, (2008), vol. 5, no. 4, pages 601 - 6
	- VAINZOF M ET AL., J MOL NEUROSCI., (2008), vol. 34, no. 3, pages 241 - 8
	- WU, H.; NAYA, F.J.; MCKINSEY, T.A.; MERCER, B.; SHELTON, J.M.; CHIN, E.R.; SIMARD, A.R.; MICHEL, R.N.; BASSEL-DUBY, R.; OLSON, E.N, "MEF2 responds to multiple calcium regulated signals in the control of skeletal muscle fiber type", EMBO J., (2000), vol. 19, pages 1963 - 1973
	- YANG, B.; JUNG, D.; MOTTO, D.; MEYER, J.; KORETZKY, G.; CAMPBELL, K.P., "SH3 domain mediated interaction of dystroglycan and Grb2", J BIOL CHEM., (1995), vol. 270, pages 11711 - 11714
	- ZHOU G; MYERS R; LI Y; CHEN Y; SHEN X; FENYK-MELODY J; WU M; VENTRE J; DOEBBER T; FUJII N, "Role of AMP-activated protein kinase in mechanism of metformin action", J CLIN INVEST., (2001), vol. 108, pages 1167 - 1174

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p